Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.

Center for Vaccine Development, University of Maryland, Baltimore, MD, United States.
Vaccine (Impact Factor: 3.49). 04/2009; 27(15):2171-6. DOI: 10.1016/j.vaccine.2009.01.097
Source: PubMed

ABSTRACT The development of a safe and effective malaria vaccine is impeded by the complexity of the Plasmodium life cycle. A vaccine that elicits both cell-mediated and humoral immune responses might be needed for protection against this multistage parasitic infection. Apical membrane antigen 1 (AMA-1) plays a key role in erythrocytic invasion but is also expressed in sporozoites and in late stage liver schizonts, where it may provide a target of protective cell-mediated immunity (CMI). A Phase 1 trial of a vaccine consisting of recombinant AMA-1 protein and the Adjuvant system AS02A was conducted in 60 Malian adults aged 18-55 years who were randomized to receive either half-dose (25 microg/0.25 ml) or full dose (50 microg/0.5 ml) FMP2.1/AS02A or a control rabies vaccine. Interleukin 5 (IL-5) and interferon-gamma (IFN-gamma) production as evaluated by ELISpot and lymphocyte proliferation were measured after in vitro AMA-1 stimulation of peripheral blood mononuclear cells (PBMCs) collected on Days 0 and 90. Post-FMP2.1/AS02A immunization mean stimulation indices were significantly elevated as were the number of IL-5 spot forming cells (SFC)/10(6) PBMC, but no difference was noted in INF-gamma production between the AMA-1/AS02A vaccinated group and the rabies group. These results provide evidence that complex immune responses can be induced by this vaccination strategy and add further impetus for the continuing clinical evaluation of this vaccine.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals naturally exposed to Plasmodium falciparum lose clinical immunity after prolonged lack of exposure. P. falciparum antigen-specific cytokine responses have been associated with protection from clinical malaria, but the longevity of Plasmodium falciparum antigen-specific cytokine responses in the absence of exposure is not well characterized. A highland area of Kenya with low and unstable malaria transmission provided an opportunity to study this question. Levels of antigen-specific cytokines and chemokines associated in previous studies with protection from clinical malaria (IFN-γ, IL-10 and TNF- α), with increased risk of clinical malaria (IL-6), or with pathogenesis of severe disease in malaria (IL-5, RANTES) were assessed by cytometric bead assay in April 2008, October 2008 and April 2009 in 100 children and adults. During the one-year study period, none had an episode of clinical P. falciparum malaria. Two patterns of cytokine responses emerged, with some variation by antigen: a decrease at 6 months (IFN-γ, IL-5) or at both 6 and 12 months (IL-10, TNF-α), or no change over time (IL-6, RANTES). These findings document that P. falciparum antigen-specific cytokine responses associated in prior studies with protection from malaria (IFN-γ, TNF-α, IL-10) decrease significantly in the absence of P. falciparum exposure, while those associated with increased risk of malaria (IL-6) do not. The study findings provide a strong rationale for future studies of antigen-specific IFN-γ, TNF-α and IL-10 responses as biomarkers of increased population-level susceptibility to malaria after prolonged lack of P. falciparum exposure.
    Infection and Immunity 06/2014; 82(9). DOI:10.1128/IAI.01924-14 · 4.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Replication-defective chimpanzee adenovirus vectors are emerging as a promising new class of genetic vaccine carriers. Chimpanzee adenovirus vectors have now reached the clinical stage and appear to be endowed with all the properties needed for human vaccine development, including high quality and magnitude of the immune response induced against the encoded antigens, good safety and ease of manufacturing on a large-scale basis. Here the authors review the recent findings of this novel class of adenovirus vectors and compare their properties to other clinical stage vaccine vectors derived from poxvirus, alphavirus and human adenovirus.
    Expert Review of Vaccines 04/2013; 12(4):379-93. DOI:10.1586/erv.13.15 · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apical Membrane Antigen-1 (AMA-1) is a leading blood stage malaria vaccine candidate. Consistent with a key role in erythrocytic invasion, AMA-1-specific antibodies have been implicated in AMA-1-induced protective immunity. AMA-1 is also expressed in sporozoites and in mature liver schizonts where it may be a target of protective cell-mediated immunity. Here, we demonstrate for the first time that immunisation with AMA-1 can induce sterile infection-blocking immunity against Plasmodium sporozoite challenge, in 80% of immunised mice. Significantly higher levels of IFN-γ/IL-2/TNF multifunctional T cells were noted in immunised compared to control mice. We also report the first identification of minimal CD8(+) and CD4(+) T cell epitopes on P. yoelii AMA-1. These data establish AMA-1 as a target of both pre-erythrocytic and erythrocytic stage protective immune responses, and validate vaccine approaches designed to induce both cellular and humoral immunity.
    Infection and immunity 07/2013; DOI:10.1128/IAI.00544-13 · 4.16 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014